He was one of the founders of Johnson & Johnson the highest revenue pharmaceutical comany for the last 3 years( could be longer)
76 billion last year.
Johnson & Johnson have the samw interests as the Gates foundation.
Merck- ans how it's killing you.
Well then. That was just a hunch based off reading their pharamseucticals preferences.
Thanks.
Well he got the title. I'm assuming yes. Will look further.
Yes. Joesph Lister was President from 1895-1900
January 30, 2012 - London – Today Johnson & Johnson joined the World Health Organization (WHO), 12 other pharmaceutical companies, the Bill & Melinda Gates Foundation, the U.S. and U.K. governments, the World Bank, and officials from endemic countries in a new, coordinated action to eliminate or control by the end of the decade 10 neglected tropical diseases (NTDs) that affect more than a billion people in the world.
Johnson & Johnson and other partners announced their commitments at an event today at the Royal College of Physicians in London, and signed onto the “London Declaration on Neglected Tropical Diseases,” to pledge new levels of collaboration and tracking and reporting of progress.
Johnson & Johnson will work with its partners on pre-clinical research and clinical development of flubendazole, a potential new treatment against parasites that cause lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness), two debilitating diseases for which current treatments do not eradicate the parasites. Elephantiasis and river blindness are among the most difficult to treat tropical diseases and afflict hundreds of millions around the world in Southeast Asia, sub-Saharan Africa, Central and South America and other tropical countries. The infections are transmitted by insect bites and caused by adult worms that lodge in the body and lay millions of larvae in the lymphatic system, blood and tissues. Current treatments effectively kill only the larvae, not adult worms, and have serious side effects.
Flubendazole, originally discovered and developed by renowned researcher Dr. Paul Janssen, founder of Johnson & Johnson’s Janssen Pharmaceutica, is a proven, effective treatment against intestinal parasites. Unlike drugs that are currently used to treat parasitic infections affecting the skin or the eyes, flubendazole has an important advantage: it kills adult parasites rather than just their larvae. However, in its current formulation, which is not absorbable, it is effective only against parasites in the stomach and intestines, but does not reach parasites lodged in blood and tissues.
Working in collaboration with other pharmaceutical partners, Johnson & Johnson will contribute scientific, supply assistance and technical expertise to Drugs for Neglected Diseases initiative (DNDi) to reformulate flubendazole to enhance its bioavailability in blood and tissues and conduct pre-clinical testing. The pre-clinical work was supported by a Gates Foundation grant to DNDi. Assuming the pre-clinical development is successful, Johnson & Johnson has agreed to co-fund clinical development and to collaborate with partners on clinical trials to develop the reformulated flubendazole. Johnson & Johnson will also obtain regulatory approval for this compound.
“Innovation is the heart of our company, and it’s critical to help people live longer, healthier lives,” said William C. Weldon, Chairman and CEO of Johnson & Johnson. “It’s our goal to bring a new, more effective and easier to administer version of our medicine flubendazole to millions of people suffering from two neglected tropical diseases, working with DNDi, the Gates Foundation, and other pharmaceutical companies.”
As part of the coordinated effort announced today, Johnson & Johnson also has committed to combating NTDs through other drug donation and collaborative research and development initiatives. The company will:
•Continue to explore the development of a new chewable formulation of mebendazole to provide treatment for younger children.
•Share scientific and technical expertise to advance R&D programs, and collaborate on product development. The company is entering into innovative licensing agreements with DNDi to share compounds and knowledge to generate new drugs for river blindness, lymphatic filariasis, sleeping sickness, Chagas and visceral leishmaniasis.
•Coordinate operational activities toward the achievement of the 2020 goals through partnership in a collective progress through a NTD scorecard that will regularly and formally track progress, including whether participating organizations are meeting their supply, research, funding and implementation commitments.
Pharmaceutical company Johnson & Johnson, along with the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation, said today they are moving forward with a large-scale efficacy trial of their new HIV vaccine.
The announcement was made on the eve of World AIDS Day tomorrow.
The vaccine trial, called “Imbokodo,” will test a mosaic vaccine, a drug capable of preventing infection from a wide range of HIV strains.
Johnson & Johnson officials are billing the product as a potential “global vaccine.”
Testing in Africa
The new phase II large-scale testing will investigate whether or not the drug will be able to safely reduce incidence of HIV infection among 2,600 female participants in sub-Saharan Africa.
Women and girls account for almost 60 percent of individuals living with HIV in eastern and southern Africa.
The announcement builds off of an earlier release this year when Johnson & Johnson first unveiled the results of their vaccine in a smaller experiment.
That vaccine yielded a 100 percent antibody response against HIV in the study participants.
Out of 350 volunteers in that trial, every participant achieved immunity against every strain of HIV.
Johnson & Johnson previously hinted at the announcement of the Imbokodo study a few months back at the Global Citizen Festival in New York City, a concert and gathering to take action on social issues, including HIV.
The company hopes to get their vaccine to market within five years
They are freaking culling the us.
Mad Scientists. Terraforming. hybrid programs, sterilization, poisoning, chimera's, organ damage, gastro damage, slow long profitable deaths.
Race eradication
They are going to unleash bio weaponry hell.
First they need to weaken our immune systems.
Second they need heavy metals in the body. (possibly nano tech.)
Third. That's why they need all the money, to transport and weaponize.
-
Money for mad scientists to create worse diseases and strain resistant. For stronger vaccinations.
5.Diseases THEY GIVE YOU with prescription medication. Over a LONG period of time.
Scarlet was the distinctive colour of the Order of the Golden Fleece, established in 1429 by Philip the Good, Duke of Burgundy (1419-67).
The Austrian Order of the Golden Fleece.
RED